Contents
pdf Download PDF pdf Download XML
90 Views
37 Downloads
Share this article
Research Article | Volume 2 Issue 1 (None, 2008)
Rituximab therapy of recalcitrant bullous dermatoses
 ,
 ,
Under a Creative Commons license
Open Access
PMID : PMC3157775
Received
Feb. 7, 2008
Published
March 29, 2008
Abstract

Background :Rituximab is a monoclonal antibody directed against CD20 cell surface antigen of B-lymphocytes. Recent studies have demonstrated effectivity in recalcitrant bullous pemphigoid. The data available on other types of autoimmune bullous disease is more scant.Main observation:Here we report on the successful adjuvant use of rituximab in mucous membrane pemphigoid and pemphigus vulgaris in two patients with the most refractory course of disease. Both patients achieved a good clinical response. Conclusions:Rituximab is a third line treatment of patients with pemphigus vulgaris and mucous membrane pemphigoid. In contrast to bullous pemphigoid, other bullous diseases do not always respond to a monotherapy with this monoclonal antibody. Nevertheless, biological therapy seems to work faster than established treatment in such cases. Risks and benefits of the treatment are discussed.

Keywords
Recommended Articles
Case Report
Concurrent Lepra Reactions; Type 1 and Type 2 in a young male patient with borderline leprosy: Clinical and Histopathological correlation
...
Published: 02/09/2025
Original Article
Comparative Evaluation of Intralesional Corticosteroid Injection and Surgical Excision in Hypertrophic Scar Treatment
...
Published: 04/06/2022
Research Article
Efficacy of supra bioavailable itraconazole and conventional itraconazole at different dosing regimens in glabrous tinea infection
Published: 02/02/2024
Research Article
Fixed drug eruption followed by lichen aureus during abatacept add-on therapy of rheumatoid arthritis
Published: 27/12/2008
© Copyright Spejalisci Dermatolodzy